| Literature DB >> 33096736 |
Daniel Catalan-Matamoros1,2, Antonio Lopez-Villegas3,4,5, Knut Tore Lappegård3,4, Remedios Lopez-Liria1,6.
Abstract
As effective communication is a key ingredient for the provision of quality healthcare services, this study aimed to explore the communication experiences in the remote monitoring of older adults with a pacemaker. The study was based on a non-masked randomized observational design. The Healthcare Communication Questionnaire and in-depth interviews were conducted for data collection. A total of 49 patients participated in the study. The study findings reveal overall positive communication experiences by pacemaker users in remote monitoring with no significant differences from users in hospital monitoring. The remote option is perceived as safe and convenient, and communicating with the clinicians from home is considered comfortable and confidential. The study provides insights into the content of communication experiences in telehealth and practical implications in healthcare contexts. In a world that increasingly relies on remote communication, it is crucial to match technologies to patient needs and assess communication with patients. This will ensure the success of new models of care and establish appropriate criteria for the use of telehealth services. These criteria are all relevant in the implementation of health technology in the future as a part of effective patient-centered care.Entities:
Keywords: cardiovascular diseases; healthcare communication; hospital monitoring; pacemaker follow-up; remote monitoring
Mesh:
Year: 2020 PMID: 33096736 PMCID: PMC7589429 DOI: 10.3390/ijerph17207678
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
The adapted version of the HCCQ—Health Care Communication Questionnaire [21].
| I was asked questions in an aggressive manner |
| I have been given answers in an aggressive manner |
| I have been treated with kindness |
| I have been treated in a rude and hasty manner |
| The healthcare provider addressed me with a smile |
| The healthcare provider was able to manage the consultation |
| The healthcare provider showed respect for my privacy |
Interview guide.
| Why did you find being home-monitored an advantage? |
| What did you like about talking to the clinicians from home? |
| What did you dislike about talking to the clinicians from home? |
| Would you have preferred to have seen the clinicians in person? Why? Why not? |
| Did you feel comfortable talking to the clinicians from home? Why? Why not? |
| Did you feel that your session was confidential? Why? Why not? |
| Have you ever had problems in conducting any data transmission from home? Yes/No |
| How many times did the doctor call you to the hospital due to findings from data transmission? |
| After your experience, what kind of monitoring/follow-up would you prefer? |
| Remote Hospital It does not matter |
Selected patient baseline characteristics by intervention status.
| Variables | All (n = 50) | Groups | ||
|---|---|---|---|---|
| Telemonitoring | Hospital Monitoring | |||
| Age | 74.84 (±11.75) | 73.68 (±14.22) | 76.00 (±8.77) | 0.676 |
| Men | 26 (52.0) | 13 (52.0) | 13 (52.0) | 1.00 |
|
| ||||
| Sick sinus syndrome | 24 (48.0) | 12 (48.0) | 12 (48.0) | 0.648 |
| Atrioventricular block | 20 (40.0) | 11 (44.0) | 9 (36.0) | |
| Chronic AF with bradycardia | 6 (12.0) | 2 (8.0) | 4 (16.0) | |
|
| ||||
| Syncope | 14 (28.0) | 8 (32.0) | 6 (24.0) | 0.812 |
| Dizziness | 25 (50.0) | 12 (48.0) | 13 (52.0) | |
| Dyspnea | 11 (22.0) | 5 (20.0) | 6 (24.0) | |
|
| ||||
| Emergency dept. | 3 (6.0) | 1 (4.0) | 2 (8.0) | 0.505 |
| Cardiology ward | 14 (28.0) | 5 (20.0) | 9 (36.0) | |
| Primary healthcare | 4 (8.0) | 2 (8.0) | 2 (8.0) | |
| Other hospitals | 29 (58.0) | 17 (68.0) | 12 (48.0) | |
|
| ||||
| DDDR | 44 (88.0) | 23 (92.0) | 21 (84.0) | 0.334 |
| VVIR | 6 (12.0) | 2 (8.0) | 4 (16.0) | |
|
| ||||
| Dyslipidemia | 27 (54.0) | 13 (52.0) | 14 (56.0) | 0.500 |
| Obesity (BMI > 30) | 1 (2.0) | 0 (0.0) | 1 (4.0) | 0.500 |
| Tachyarrhythmia | 18 (36.0) | 7 (28.0) | 11 (44.0) | 0.189 |
| Hypertension | 32 (64.0) | 17 (68.0) | 15 (60.0) | 0.384 |
|
| ||||
| None | 18 (36.0) | 11 (44.0) | 7 (28.0) | 0.388 |
| Others | 10 (20.0) | 6 (24.0) | 4 (16.0) | |
| Coronary heart diseases | 22 (44.0) | 8 (32.0) | 14 (56.0) | |
| Antiaggregants | 18 (36.0) | 8 (32.0) | 10 (40.0) | 0.384 |
| Anticoagulants | 25 (50.0) | 10 (40.0) | 15 (60.0) | 0.129 |
| Antiarrhythmics | 18 (36.0) | 7 (28.0) | 11 (44.0) | 0.189 |
| Antihypertensives | 32 (64.0) | 18 (72.0) | 14 (56.0) | 0.189 |
n = 50 (Remote monitoring group: 25; Hospital monitoring group: 25). Values are expressed as means or proportions. DDDR: Bicameral pacemaker with two electrodes placed in the atrium and in the ventricle; VVIR: Unicameral pacemaker with an electrode in the ventricle with the ability to modulate the frequency of stimulation; BMI: Body mass index. Note: this table has been previously published in a previous article [33].
Follow-up general information at six months.
| Variables | All (n = 49) | Groups | ||
|---|---|---|---|---|
| Telemonitoring | Hospital Monitoring | |||
| Number of transmissions from hospital N (%) | ||||
| 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.26 |
| 1 | 41 (83.7) | 21 (84.0) | 20 (83.3) | |
| 2 | 6 (12.2) | 2 (8.0) | 4 (16.7) | |
| 3 | 2 (4.1) | 2 (8.0) | 0 (0.0) | |
| Number of transmissions from patient’s home N (%) | ||||
| 0 | 29 (59.2) | 5 (20.0) | 24 (100) | <0.001 |
| 3–5 | 15 (30.6) | 15 (60.0) | 0 (0.0) | |
| 6–8 | 5 (10.2) | 5 (20.0) | 0 (0.0) | |
| Extra transmissions from patient’s home N (%) | ||||
| 0 | 45 (91.8) | 21 (84.0) | 24 (100) | 0.12 |
| 1 | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
| 3 | 3 (6.2) | 3 (12.0) | 0 (0.0) | |
| Cardiovascular events N (%) | ||||
| None | 46 (93.9) | 23 (92.0) | 23 (95.8) | 0.40 |
| PCI | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
| Angina | 1 (2.0) | 0 (0.0) | 1 (4.2) | |
| Lead dislodgement | 1 (2.0) | 1 (2.0) | 0 (0.0) | |
| Calls/letters sent to the patients N (%) | ||||
| 0 | 27 (55.1) | 4 (16.0) | 23 (95.8) | <0.001 |
| 1 | 21 (42.9) | 20 (80.0) | 1 (4.2) | |
| 3 | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
| Changes in medication N (%) | ||||
| 0 | 33 (67.3) | 17 (68.0) | 16 (66.7) | 0.11 |
| 1 | 7 (14.3) | 5 (20.0) | 2 (8.3) | |
| 2 | 3 (6.1) | 1 (4.0) | 2 (8.3) | |
| 3 | 4 (8.2) | 0 (0.0) | 4 (16.7) | |
| 4 | 2 (4.1) | 2 (8.0) | 0 (0.0) | |
| Changes in pacemaker’s programming N (%) | ||||
| 0 | 34 (69.4) | 16 (64.0) | 18 (75.0) | 0.34 |
| 1 | 13 (26.5) | 7 (28.0) | 6 (25.0) | |
| 2 | 2 (4.1) | 2 (8.0) | 0 (0.0) | |
| Number of hospitalizations (related or not to pacemaker’s implant) N (%) | ||||
| 0 | 30 (61.2) | 14 (56.0) | 16 (66.7) | 0.55 |
| 1 | 14 (28.6) | 7 (28.0) | 7 (29.2) | |
| 2 | 4 (8.2) | 3 (12.0) | 1 (4.2) | |
| 5 | 1 (2.0) | 1 (2.0) | 0 (0.0) | |
| Number of hospitalization days (related or not to pacemaker’s implant) N (%) | ||||
| 0 | 30 (61.2) | 14 (56.0) | 16 (66.7) | 0.54 |
| 1–5 | 12 (24.5) | 6 (24.0) | 6 (25.1) | |
| 6–10 | 4 (8.1) | 2 (8.0) | 2 (8.4) | |
| +10 | 3 (6.0) | 3 (12.0) | 0 (0.0) | |
| Reasons for hospitalization N (%) | ||||
| None | 30 (61.2) | 14 (56.0) | 16 (66.7) | 0.37 |
| Others | 6 (12.3) | 3 (12.0) | 3 (12.5) | |
| Cancer | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
| Coronary problems | 9 (18.4) | 4 (16.0) | 5 (20.8) | |
| Pacemaker dysfunction | 3 (6.1) | 3 (12.0) | 0 (0.0) | |
n = 50 (Remote monitoring group: 25; Hospital monitoring group: 24). Values are expressed as means or proportions. PCI: Percutaneous coronary intervention. Note: this table has been published in a previous article [33].
Results derived from the adapted version of the Health Care Communication Questionnaire (HCCQ).
| Questions | Answering Categories | Remote Monitoring Group * | Hospital Monitoring Group * | |
|---|---|---|---|---|
| Question 1 | 1 = Not at all; | 1 (1, 5) | 1 (1, 1) | 0.383 |
| Question 2 | 1 (1, 2) | 1 (1, 1) | 0.332 | |
| Question 3 | 5 (2, 5) | 5 (3, 5) | 0.363 | |
| Question 4 | 1 (1, 3) | 1 (1, 1) | 0.332 | |
| Question 5 | 4 (2, 5) | 5 (3, 5) | 0.431 | |
| Question 6 | 5 (2, 5) | 5 (3, 5) | 0.718 | |
| Question 7 | 5 (1, 5) | 5 (3, 5) | 0.379 |
* Data presented as median (min., max.).
Quotes from participants in the remote monitoring group, 12 months after surgery.
| “I felt safe with this continuous follow-up”, participant number 1. |
| “I feel that the session was confidential, I trust in the system”, participant number 16. |
| “It was comfortable to speak with the clinicians from home because I got the answers I needed”, participant number 22. |
| “Talking to the clinicians from home was safe”, participant number 34. |
| “One of the main advantages for the remote monitoring is that I do not have to travel to the hospital”, participant number 47. |